Table 1.
Demographic and Clinical Characteristics
| Sex | Male | 65 | 68.4% |
| Female | 30 | 31.6% | |
| Race | White | 81 | 85.3% |
| Hispanic | 6 | 6.3% | |
| African-American | 8 | 8.4% | |
| Age | <55 | 29 | 30.5% |
| 55–64 | 27 | 28.4% | |
| >64 | 39 | 41.1% | |
| Cell Differentiation | Well differentiated | 20 | 22.2% |
| Moderately differentiated | 54 | 60.0% | |
| Poorly differentiated | 16 | 17.8% | |
| Undifferentiated | - | - | |
| Unknown | 5 | ||
| Primary Tumor Site | Oral Cavity | 56 | 58.9% |
| Oropharynx | 12 | 12.6% | |
| Hypopharynx | 8 | 8.4% | |
| Larynx | 13 | 13.7% | |
| Other | 5 | 5.3% | |
| >1 Primary | 1 | 1.1% | |
| Pathologic T Stage | pT1 | 24 | 25.5% |
| pT2 | 32 | 34.0% | |
| pT3 | 15 | 16.0% | |
| pT4 | 22 | 23.4% | |
| pTx/is | 1 | 1.1% | |
| missing | 1 | 1.1% | |
| Pathologic N Stage | pNo/Nx | 46 | 48.9% |
| pN+ | 48 | 51.1% | |
| missing | 1 | ||
| Status of Primary Tumor |
Eradicated but Local Recurrence |
9 | 9.7% |
| Residual Disease After Primary Surgery |
14 | 15.1% | |
| Untreated | 70 | 75.3% | |
| Unknown | 2 | ||
| Clinical TNM Stage | I | 8 | 9.9% |
| II | 15 | 18.5% | |
| III | 23 | 28.4% | |
| IV | 35 | 43.2% | |
| Unknown | 14 | ||
| Treatment | Surgery Alone | 33 | 34.7% |
| Surgery & Post-Operative Treatment |
45 | 47.4% | |
| Salvage Treatment | 17 | 17.9% | |
| Smoking History | Never Smoked | 16 | 17.4% |
| Pipe/Cigar Only | 4 | 4.3% | |
| <20 Pack Years | 9 | 9.8% | |
| 20–40 Pack Years | 26 | 28.3% | |
| ≥40 Pack Years | 37 | 40.2% | |
| Unknown | 3 | ||
| Average Alcohol Consumption |
<10 oz/wk | 52 | 59.8% |
| 10–20 oz/wk | 16 | 18.4% | |
| >20 oz/wk | 19 | 21.8% | |
| Unknown | 8 | ||
| Weight Loss in Previous 6 months |
<5% | 61 | 72.6% |
| 5–9.9% | 12 | 14.3% | |
| 10–19.9% | 8 | 9.5% | |
| ≥20% | 3 | 3.6% | |
| Unknown | 11 | ||
| Performance Status | 0 | 68 | 73.9% |
| 1 | 20 | 21.7% | |
| 2 | 4 | 4.3% | |
| Unknown | 3 | ||
| Did Primary Extend to Adjacent Structures? |
No | 53 | 56.4% |
| Yes | 41 | 43.6% | |
| Unknown | 1 | ||
| Clinical T Stage | T1 | 17 | 18.1% |
| T2 | 27 | 28.7% | |
| T3 | 27 | 28.7% | |
| T4 | 23 | 24.5% | |
| Unknown | 1 | ||
| Clinical N Stage | N0 | 56 | 60.2% |
| N1 | 17 | 18.3% | |
| N2 | 17 | 18.3% | |
| N3 | 3 | 3.2% | |
| Unknown | 2 | ||
| Mutation Status | Disruptive | 34 | 36% |
| Non-Disruptive | 61 | 64% | |